Search
Returning search results with filters:
Remove filter for
Issue: Health products
Remove filter for
Type: Health professional risk communication
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 2 of 2 items.
Bamlanivimab - Potential Risk of Treatment Failure Due to Circulation of Resistant SARS-CoV-2 Variants
AlertHealth professional risk communication | 2021-04-28
Authorization of Bamlanivimab with English-only Labels for Use in Relation to the COVID-19 Pandemic
AlertHealth professional risk communication | 2020-12-18